<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02019667</url>
  </required_header>
  <id_info>
    <org_study_id>140033</org_study_id>
    <secondary_id>14-N-0033</secondary_id>
    <nct_id>NCT02019667</nct_id>
  </id_info>
  <brief_title>Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency</brief_title>
  <official_title>Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Objective:

      To perform a clinical trial assessing the safety, tolerability and efficacy of the GABA(B)
      receptor antagonist SGS-742 in patients with SSADH deficiency.

      Study Population:

      Twenty-two children and adults with SSADH deficiency.

      Design:

      Double-blind, cross-over, phase II clinical trial. SGS-742 is a GABA (B) receptor antagonist
      that has shown to be safe and well-tolerated in clinical trials in adults with cognitive
      impairment. In addition, preliminary data in the SSADH knockout mouse model suggest efficacy
      in this specific syndrome. The primary outcome measure will be a change in the Auditory
      Comprehension subtest of the Neuropsychological Assessment Battery Language Module score; the
      secondary outcome measure will be a change in cortical excitation and inhibition measured by
      transcranial magnetic stimulation (TMS). Additional evaluations will include neurological and
      neuropsychological examinations, magnetic resonance spectroscopy and CSF collection to
      measure GABA levels. The trial will have a baseline phase in which each patient will undergo
      a neurological examination and a neuropsychological evaluation. During the subsequent
      treatment phase, patients will be randomized to SGS-742, supplied by IRIX Pharmaceuticals,
      and based on weight given a maximum tolerated dose not to exceed 600 mg t.i.d. orally, or
      placebo, each for 6 months. Patients will then have repeat TMS, neurological and
      neuropsychological evaluations, followed by cross-over to the alternate treatment arm, and
      re-evaluation after 6 months.

      Outcome Measures:

      The primary outcome measures for drug efficacy will be performance on neuropsychological
      testing and responses to parent questionnaire. The secondary outcome measure will be TMS
      parameters of cortical excitation and inhibition. The outcome measures for safety will
      include clinical examination and neuropsychological tests.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:

      To perform a clinical trial assessing the safety, tolerability and efficacy of the GABA(B)
      receptor antagonist SGS-742 in patients with SSADH deficiency.

      Study Population:

      Twenty-two children and adults with SSADH deficiency.

      Design:

      Double-blind, cross-over, phase II clinical trial. SGS-742 is a GABA (B) receptor antagonist
      that has shown to be safe and well-tolerated in clinical trials in adults with cognitive
      impairment. In addition, preliminary data in the SSADH knockout mouse model suggest efficacy
      in this specific syndrome. The primary outcome measure will be a change in the Auditory
      Comprehension subtest of the Neuropsychological Assessment Battery Language Module score; the
      secondary outcome measure will be a change in cortical excitation and inhibition measured by
      transcranial magnetic stimulation (TMS). Additional evaluations will include neurological and
      neuropsychological examinations, magnetic resonance spectroscopy and CSF collection to
      measure GABA levels. The trial will have a baseline phase in which each patient will undergo
      a neurological examination and a neuropsychological evaluation. During the subsequent
      treatment phase, patients will be randomized to SGS-742, supplied by IRIX Pharmaceuticals,
      and based on weight given a maximum tolerated dose not to exceed 600 mg t.i.d. orally, or
      placebo, each for 6 months. Patients will then have repeat TMS, neurological and
      neuropsychological evaluations, followed by cross-over to the alternate treatment arm, and
      re-evaluation after 6 months.

      Outcome Measures:

      The primary outcome measures for drug efficacy will be performance on neuropsychological
      testing and responses to parent questionnaire. The secondary outcome measure will be TMS
      parameters of cortical excitation and inhibition. The outcome measures for safety will
      include clinical examination and neuropsychological tests.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 20, 2013</start_date>
  <completion_date type="Anticipated">November 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 29, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance on neurological testing and responses to parent questionnaire</measure>
    <time_frame>on-going</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TMS parameters of cortical excitation and inhibition</measure>
    <time_frame>on-going</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical examination and neuropsychological tests</measure>
    <time_frame>on-going</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Metabolic Disease</condition>
  <condition>Seizures</condition>
  <arm_group>
    <arm_group_label>phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>study drug or placebo (blinded)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>phase I for 6 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug or placebo (blinded) for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>phase I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>study drug or placebo (blinded)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>phase II crossover</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>crossover study drug or placebo blinded</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGS-742</intervention_name>
    <arm_group_label>phase II</arm_group_label>
    <arm_group_label>phase I for 6 months</arm_group_label>
    <arm_group_label>phase I</arm_group_label>
    <arm_group_label>phase II crossover</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>phase I</arm_group_label>
    <arm_group_label>phase II crossover</arm_group_label>
    <arm_group_label>phase I for 6 months</arm_group_label>
    <arm_group_label>phase II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA

          -  Aged 4 years or older

          -  4-hydroxybutyric aciduria (gamma-hydroxybutyric aciduria) on two separate tests

          -  Documented succinic semialdehyde dehydrogenase enzyme deficiency

          -  Patients must have clinical features consistent with SSADH deficiency including
             developmental delay especially deficit in expressive language, hypotonia, ataxia,
             seizures, and other neuropsychiatric symptoms including sleep disturbances , attention
             deficit, anxiety, obsessivecompulsive disorder, and autistic traits

          -  During the study, women of child-bearing potential must use a reliable method of birth
             control until one month after the final drug taper is complete.

        EXCLUSION CRITERIA

          -  Current alcohol use (&gt;14 drinks/wk in men and &gt;7 drinks/wk in women or or recreational
             drug use

          -  Contraindications to MRI: metal in the body including pacemakers, medication pumps,
             aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or
             cochlear implants), shrapnel fragments, permanent eye liner or small metal fragments
             in the eye that welders and other metal workers may have

          -  Claustrophobia

          -  Cannot lie comfortably flat on the back for up to 2h in the MRI scanner

          -  Patients with a history of other major medical disorders with clinical fluctuations,
             or requiring therapy that might affect study participation or drug response such as
             severe depression or psychoses, renal or hepatic disease.

          -  Patients requiring treatment with drugs known to affect the GABAergic system,
             including vigabatrin and benzodiazepines.

          -  Pregnant and lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara K Inati, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Neurological Disorders and Stroke (NINDS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington State University</name>
      <address>
        <city>Pullman</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2014-N-0033.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Al-Essa MA, Bakheet SM, Patay ZJ, Powe JE, Ozand PT. Clinical, fluorine-18 labeled 2-fluoro-2-deoxyglucose positron emission tomography (FDG PET), MRI of the brain and biochemical observations in a patient with 4-hydroxybutyric aciduria; a progressive neurometabolic disease. Brain Dev. 2000 Mar;22(2):127-31.</citation>
    <PMID>10722966</PMID>
  </reference>
  <reference>
    <citation>Arnold S, Berthele A, Drzezga A, TÃ¶lle TR, Weis S, Werhahn KJ, Henkel A, Yousry TA, Winkler PA, Bartenstein P, Noachtar S. Reduction of benzodiazepine receptor binding is related to the seizure onset zone in extratemporal focal cortical dysplasia. Epilepsia. 2000 Jul;41(7):818-24.</citation>
    <PMID>10897152</PMID>
  </reference>
  <reference>
    <citation>Arnulf I, Konofal E, Gibson KM, Rabier D, Beauvais P, Derenne JP, Philippe A. Effect of genetically caused excess of brain gamma-hydroxybutyric acid and GABA on sleep. Sleep. 2005 Apr;28(4):418-24.</citation>
    <PMID>16171286</PMID>
  </reference>
  <verification_date>April 10, 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2013</study_first_submitted>
  <study_first_submitted_qc>December 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2013</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GABA</keyword>
  <keyword>Seizures</keyword>
  <keyword>Neurotransmitters</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Amino Acid Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Developmental Disabilities</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>(3-aminopropyl)(n-butyl)phosphinic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

